Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies.
Taha et al.·The oncologistImpact 3.1
SchadenGRADEModerat148 Zitate
Stichproben = 140 Pat.
Dauer2015-2016
KontrolleNivolumab allein
EndpunktTumoransprechrate
Verblindungn.a.
DesignKohortenstudie
”Kernaussage
Cannabiskonsum während Nivolumab-Therapie reduzierte die Ansprechrate signifikant (37,5% vs. 15,9%, p=0,016), ohne Auswirkung auf progressionsfreies Überleben oder Gesamtüberleben.
Zusammenfassung
Retrospektive Kohortenstudie n=140 (89 Nivolumab mono, 51 Nivolumab+Cannabis) bei fortgeschrittenem Melanom/NSCLC/Nierenzell-Ca; Cannabis-Gebrauch reduzierte Tumor-Response-Rate signifikant (37,5% vs. 15,9%, p=0.016, OR=3.13, 95% CI 1.24–8.1), ohne Effekt auf PFS oder OS. THC/CBD-Prozentanteile hatten keinen Einfluss auf RR (p=0.393/0.116).
P
PopulationErwachsene mit fortgeschrittenem Melanom, nicht-kleinzelligem Lungenkarzinom oder klarzelligem Nierenzellkarzinom unter Nivolumab-Therapie, n=140 (89 Nivolumab allein, 51 Nivolumab plus Cannabis)
I
InterventionNivolumab plus Cannabis (von sechs Versorgungsunternehmen) während der Immuntherapie
C
KontrolleNivolumab allein (ohne Cannabis)
O
OutcomeSignifikant reduzierte Ansprechrate in der Cannabis-Gruppe (15,9% vs. 37,5%; p=0,016, OR=3,13, 95%-KI 1,24–8,1); kein signifikanter Unterschied bei PFS oder OS
Vertrauen in die Evidenz
Sehr niedrigNiedrigModeratHoch
Moderat
Dritte von vier GRADE-Stufen, die Effektschätzung ist wahrscheinlich verlässlich.
Qualitätsprofil
Größe★★★★★
Verblindung—
EffektstärkeSchaden
Zitate / Jahr★★★★★
Autoren
Taha T, Meiri D, Talhamy S, Wollner M, Peer A, Bar-Sela G
Background: There has been a significant increase in the use of immunotherapy and cannabis recently, two modalities that have immunomodulatory effects and may have possible interaction. We evaluated the influence of cannabis use during immunotherapy treatment on response rate (RR), progression-free survival (PFS), and overall survival (OS).
Subjects, Materials, And Methods: In this retrospective, observational study, data were collected from the files of patients treated with nivolumab in the years 2015-2016 at our hospital, and cannabis from six cannabis-supplying companies. Included were 140 patients (89 nivolumab alone, 51 nivolumab plus cannabis) with advanced melanoma, non-small cell lung cancer, and renal clear cell carcinoma. The groups were homogenous regarding demographic and disease characteristics. A comparison between the two arms was made.
Results: In a multivariate model, cannabis was the only significant factor that reduced RR to immunotherapy (37.5% RR in nivolumab alone compared with 15.9% in the nivolumab-cannabis group (p = .016, odds ratio = 3.13, 95% confidence interval 1.24-8.1). Cannabis use was not a significant factor for PFS or OS. Factors affecting PFS and OS were smoking (adjusted hazard ratio [HR] = 2.41 and 2.41, respectively (and brain metastases (adjusted HR = 2.04 and 2.83, respectively). Low performance status (adjusted HR = 2.83) affected OS alone. Tetrahydrocannabinol and cannabidiol percentages did not affect RR in any group (p = .393 and .116, respectively).
Conclusion: In this retrospective analysis, the use of cannabis during immunotherapy treatment decreased RR, without affecting PFS or OS and without relation to cannabis composition. Considering the limitations of the study, further prospective clinical study is needed to investigate possible interaction.
Implications For Practice: Although the data are retrospective and a relation to cannabis composition was not detected, this information can be critical for cannabis users and indicates that caution is required when starting immunotherapy.